Skip to main navigation

Contact Us
Global
- International
- Canada
- France
- Germany
- Italy
- Japan
- Netherlands
- Spain

About Amicus
- About Amicus
- Chairman’s Welcome
- Leadership
- Belief Statement
- Contact Us
- Message from BIO
Patient Advocacy
- Patient Advocacy
- Disease Information
- Rare Stories
- Patient Advisory Boards
- Corporate Giving
- Resources
- Expanded Access
Programs & Pipeline
- Programs & Pipeline
- Our Pipeline
- Fabry Disease
- Pompe Disease
- Batten Disease
- Additional Preclinical Programs
- Clinical Trials
- Platform Technologies
- Journal Articles
- Publications & Posters
Product
- Product
- Galafold^®
- Amicus Assist™
Responsibility
- Responsibility
- Ethics & Compliance
- Global Medical Affairs
- Corporate Giving
- Healing Beyond Disease
- ESG Report
Investors & Media
- Investors & Media
- Investor Relations
- Senior Management Team
- Board of Directors
- Corporate Governance
- Press Releases
- Events & Presentations
- Annual Reports and Proxies
- SEC Filings
- Stock Performance
- Investor FAQs
- Contact Us
- Sign Up for Email Alerts
- Featured Coverage
- Electronic Press Kit
Careers
- Careers
- Overview
- Search

Investors

Press Releases

Press Releases

Year

August 4, 2022

Amicus Therapeutics Announces Second Quarter 2022 Financial Results

July 26, 2022

Amicus Therapeutics to Announce Second Quarter 2022 Financial Results on August 4, 2022

June 8, 2022

Amicus Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

May 10, 2022

Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA

May 9, 2022

Amicus Therapeutics Announces First Quarter 2022 Financial Results

May 4, 2022

Amicus Therapeutics to Present at the Bank of America 2022 Healthcare Conference

April 26, 2022

Amicus Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022

April 19, 2022

Amicus Announces Issuance of New U.S. Composition of Matter Patent for Galafold® (migalastat), Strengthening Patent Protection Through 2038

March 16, 2022

Amicus Therapeutics Announces Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease at the 2022 MDA Clinical & Scientific Conference

March 10, 2022

Amicus Therapeutics Announces Presentation and Posters at the 2022 MDA Clinical & Scientific Conference

Pagination

Current page 1
Page 2
Next page
Last page

About Amicus

Patient Advocacy

Programs & Pipeline

Product
- Overview
- Amicus Assist™

Responsibility

Investors & Media

Careers
- Overview
- Search

Social Media
- Twitter
- YouTube
- LinkedIn

Copyright © 2022 Amicus Therapeutics. All rights reserved. NP-AT-ALL-00011119

Cookies Statement
Terms of Use
Privacy Notice
Privacy Shield Policy

The site you are about to enter is intended for US healthcare professionals.

Please confirm you are a US healthcare professional.

I am a US healthcare professional I am not a US healthcare professional